News about Global Pharma

MJFF Selects ONTOFORCE DISQOVER to Enhance Integration and Access of PD Research

DISQOVER, ONTOFORCE’s advanced knowledge discovery platform, will support MJFF’s Targets to Therapies Initiative, a program aimed to expand the number of promising, druggable biological targets within the Parkinson’s disease (PD) translational pipeline.

Global Pharma | 04/04/2025 | By Aishwarya |  173

Entos Pharmaceuticals and Circio to Develop Novel Platform for CircVec Circular RNA Delivery

Under the collaboration, Entos will develop and validate PLV-formulations of Circio´s circVec DNA vectors and perform technical testing in vivo.

Global Pharma | 04/04/2025 | By Aishwarya |  301

Append Medical Appoints Shlomi Nachman as Chairman of the Board

Append Medical announce the appointment of Shlomi Nachman as Chairman of the Board. This strategic move reflects the company's commitment to advancing its mission of reducing stroke risks for patients with atrial fibrillation through groundbreaking technology.

Global Pharma | 03/04/2025 | By Manvi |  150

Gland Pharma Secures USFDA Approval for Acetaminophen Injection

Gland Pharma has received USFDA approval for its Acetaminophen Injection, a bioequivalent version of B. Braun Medical’s product, used for managing mild to moderate pain. The company plans to launch the product soon through its marketing partner.

Global Pharma | 03/04/2025 | By Manvi |  516

Novartis Gets FDA Accelerated Approval for Vanrafia

Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo1. It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.

Global Pharma | 03/04/2025 | By Aishwarya |  363

Lupin Acquires Renascience to Expand its Footprint in United Kingdom

With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary.

Global Pharma | 03/04/2025 | By Aishwarya |  376

Syntegon Plans to Relocate and Expand Business Growth at New Sites

The activities of the Pharma Solid business unit located in Waiblingen will move to a dedicated pharma site in neighboring Fellbach in the second half of 2025.

Global Pharma | 03/04/2025 | By Aishwarya |  502

Alembic Pharmaceuticals Secures USFDA Nod for Key GERD Injection Drug

The drug is a therapeutic equivalent to Protonix I.V., originally developed by Wyeth Pharmaceuticals, and is used to manage gastroesophageal reflux disease (GERD), erosive esophagitis, and certain rare hypersecretion conditions like Zollinger-Ellison Syndrome in adults.

Global Pharma | 02/04/2025 | By Aishwarya |  278

Freudenberg Achieves Stable Growth in 2024 with Increased Profit Margins

. Operating profit grew by about 4.7 percent, reaching EUR 1,132.4 million, up from EUR 1,081.6 million last year.

Global Pharma | 02/04/2025 | By Aishwarya |  424

Azenta Launches Automated Plate Seal Remover to Boost Lab Performance

Designed for unattended operation, the Automated Plate Seal Remover is an ideal solution for life science labs that routinely remove microplate seals.

Global Pharma | 02/04/2025 | By Aishwarya |  261